Cancer immunotherapy: breaking the barriers to harvest the crop
about
Adoptive T cell therapy for cancer in the clinicLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaImmunosuppressive strategies that are mediated by tumor cellsProteomics in cancer vaccine development.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing.Immunotherapy for lung cancers.Dendritic cell subsets in health and disease.Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.A2A adenosine receptor protects tumors from antitumor T cells.Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patientsOpportunities and challenges in the development of experimental drug combinations for cancer.Dendritic cells as therapeutic vaccines against cancer.Immunotherapy for pancreatic cancer - science driving clinical progress.Yeast whole glucan particle (WGP) beta-glucan in conjunction with antitumour monoclonal antibodies to treat cancer.Emerging melanoma vaccines.Immunoepigenetics: the unseen side of cancer immunoediting.Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.Immunotherapy and immunoescape in colorectal cancer.Twelve immunotherapy drugs that could cure cancers.Recent advances of cocktail chemotherapy by combination drug delivery systems.Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.Dendritic cells: a critical player in cancer therapy?Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?Incorporating tyrosine kinase inhibitors into treatment regimens for AML and ALL: is there a right or wrong way?The future of glioblastoma therapy: synergism of standard of care and immunotherapy.Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.Targeted therapies for renal cell carcinoma.Eradication of established tumors in mice by a combination antibody-based therapy.Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer.Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model.Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.Serum Soluble Interleukin-2 Receptor is Increased in Malnourished and Immunosuppressed Patients With Gastric and Colorectal Cancer: Possible Influence of Myeloid-Derived Suppressor Cells.Dual Chemodrug-Loaded Single-Walled Carbon Nanohorns for Multimodal Imaging-Guided Chemo-Photothermal Therapy of Tumors and Lung Metastases.Nicotine stimulated dendritic cells could achieve anti-tumor effects in mouse lung and liver cancer.CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease
P2860
Q24680405-C465D934-AFE4-4AC3-A681-9CB14D046A89Q29620812-1D662C3F-8FEB-43AF-99BC-1018D7566AE4Q29636247-DCF6EEE2-718C-4ABD-8BDB-BF4E52E62270Q33215044-770FA447-268B-4FE6-9A3F-F57215351444Q34103645-3597860D-4383-454C-B8FE-6DBCBD625533Q34204137-A540E711-87A5-4CE3-AC29-09785AE1FB17Q34557611-8978F9DB-7E5C-454F-9A78-330CB483133AQ34582889-F06F6086-29E5-40A6-938A-888C3A1B70C0Q34887495-39906AE6-99BE-4A97-978D-4D9FBC7C618AQ35016529-A04F500B-626D-4472-A724-1FFF15334F12Q35021619-EDC8D28E-334C-48A3-BF4D-7B7660CCEE99Q35555293-53143E29-ED8A-45C6-BEB4-20EBBB43F5DEQ36085614-5D80F9E3-5FDB-43E7-82D3-7EE75589D839Q36133140-E91A905B-1E49-476E-8642-7806A9C4F1A7Q36150511-88D91595-39D5-489C-A366-C47C2524543CQ36150640-A1D544C5-22DD-4748-962E-0E5746BDBAC8Q36666346-0065575D-9177-4659-A446-982AD3FD6B96Q36915898-68DFA555-0D39-4E94-B773-ECAA9C1984CDQ36962460-8D57871D-11D3-4AF6-90A0-EE1BCFCC8C50Q36996316-31646A73-26B4-4FAB-AE24-B0702B80F348Q37118201-41EDE263-19EA-43A8-8795-6A6EB383D678Q37206908-6D72B6BD-BD0C-425F-A60B-03E1A674D219Q37259634-9C6C783B-3210-4AEF-999C-5A321E143BFCQ37276138-E331D685-180D-4169-99DB-BBD38D108A5FQ37773303-B2DFB73F-4FFE-46BB-A98A-D27996870575Q38196347-41BE7CDD-17CF-4C3E-9312-1A79CC1E1249Q38255481-7308538D-46EF-435B-BCC7-BDAC02484B09Q38332777-C89F59D5-F467-4C8D-8307-981DFB10A592Q39425380-BDAA6B54-3AAD-4929-9DF4-D455C87D1648Q40282761-9DD2081F-6DA1-496F-B8C7-F280D33ABD74Q41920864-34280EF8-4310-4101-B4B2-9501A463AD59Q43190686-35C581C9-7676-4416-B067-E46235C55186Q45884086-B21BE820-3CA6-4329-842A-ECE426465183Q47119947-8C4E16CA-0796-4CAE-817E-20A12CC578DAQ52647638-75046FDC-A2DB-4043-A958-455CEA4DC5D6Q54641467-F3A12159-ED86-400E-9014-5988C0D59DBEQ56901286-E0CA25AE-E739-4871-B1A2-ABAD3482E31B
P2860
Cancer immunotherapy: breaking the barriers to harvest the crop
description
im September 2004 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2004
@uk
name
Cancer immunotherapy: breaking the barriers to harvest the crop
@en
Cancer immunotherapy: breaking the barriers to harvest the crop
@nl
type
label
Cancer immunotherapy: breaking the barriers to harvest the crop
@en
Cancer immunotherapy: breaking the barriers to harvest the crop
@nl
prefLabel
Cancer immunotherapy: breaking the barriers to harvest the crop
@en
Cancer immunotherapy: breaking the barriers to harvest the crop
@nl
P2860
P356
P1433
P1476
Cancer immunotherapy: breaking the barriers to harvest the crop
@en
P2093
Drew Pardoll
P2860
P2888
P304
P356
10.1038/NM0904-887
P407
P577
2004-09-01T00:00:00Z